Clinical Trial Update: MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating MEDI4736 (durvalumab) and tremelimumab in metastatic HER2-negative breast cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Northwestern University | Conditions: Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Status: COMPLETED | Results posted: 2021-04-23